Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 3/20 | 0.38 |
| ▸ | FNTB | P49356 | 3/20 | 0.38 |
| ▸ | SQLE | Q14534 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18887568 | 1.00 | NR1I2 (0.53) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL5078672 | 0.93 | NR1I2 (0.61) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2834965 | 0.88 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2836288 | 0.88 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2833728 | 0.88 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2838252 | 0.88 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2833754 | 0.85 | NR1I2 (0.73) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL4841326 | 0.84 | NR1I2 (0.54) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL6315751 | 0.84 | NR1I2 (0.46) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2832173 | 0.84 | NR1I2 (0.61) | NR1I2LMNAPGRKDM1AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375133-B2 | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20050065096-A1 | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065096-A1 | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CYP11B2, CYP11B1, PTGER1 | NR1I2 635/4885LMNA 969/4885PGR 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.